Abivax S.A.
Clinical trials sponsored by Abivax S.A., explained in plain language.
Biotech developing treatments for inflammatory diseases and viral infections.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Healthy volunteers needed to Taste-Test a new drug pill Results expected Sep 2026 (estimated)
- New pill could tame Crohn's Flare-Ups Results expected Dec 2026 (estimated) May already have reported ↗
-
New pill could tame Crohn's Flare-Ups
Disease control Recruiting nowThis study tests an experimental oral drug called obefazimod in 212 adults with moderate-to-severe Crohn's disease who haven't responded well to other treatments. Participants receive either obefazimod or a placebo daily for 12 weeks (induction), then up to 40 more weeks (mainten…
Phase 2 • Sponsor: Abivax S.A. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Healthy volunteers needed to Taste-Test a new drug pill
Knowledge-focused Recruiting nowThis study is testing a new, smaller minitablet version of the drug obefazimod in 44 healthy adults aged 18 to 55. The goal is to see how the body absorbs the minitablet compared to the current capsule and to check if the minitablet tastes okay. Participants will take a single do…
Phase 1 • Sponsor: Abivax S.A. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC